Skip to main
SPRY

SPRY Stock Forecast & Price Target

SPRY Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ARS Pharmaceuticals is a biopharmaceutical company that has recently launched its proprietary composition of epinephrine with an absorption enhancer, Neffy, for intranasal delivery. This makes Neffy the first no-needle, pain-free treatment for Type I allergic reactions on the market, with comparable profiles to intramuscular epinephrine. The company's positive outlook is based on expectations of strong US and global sales, supported by a strategic plan focused on physician outreach, removal of bottlenecks, a robust DTC campaign and favorable market positioning in the pediatric segment. The company's diversified revenue streams, including its commercial partnerships and access to the Florida Medicaid formulary, further strengthens its growth potential.

Bears say

ARS Pharmaceuticals is facing challenges in securing commercial formulary wins and gaining payer coverage for neffy, with no new positive developments in the July 2026 cycle and the next opportunity for coverage not expected until January 2027. Additionally, high utilization and regulatory threats may impact the company's profitability, and pharmacy reimbursement continues to be a headwind. However, upcoming data from a Phase 2b study for neffy's use in chronic suppressive therapy and the launch of a new product, ARS-2, may provide upside for the company. Leadership changes and competition in the PBM market also present potential risks. Ultimately, the company's success will depend on its ability to successfully navigate these challenges and generate strong sales for neffy and ARS-2.

SPRY has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ARS Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ARS Pharmaceuticals Inc (SPRY) Forecast

Analysts have given SPRY a Buy based on their latest research and market trends.

According to 3 analysts, SPRY has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ARS Pharmaceuticals Inc (SPRY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.